160 related articles for article (PubMed ID: 15917163)
1. Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene.
Tsalikis T; Zepiridis L; Zafrakas M; Dinas K; Bontis J
Maturitas; 2005 Jun; 51(2):215-8. PubMed ID: 15917163
[TBL] [Abstract][Full Text] [Related]
2. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
3. Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women.
Christodoulacos G; Panoulis C; Botsis D; Rizos D; Kassanos D; Creatsas G
Maturitas; 2002 May; 42(1):77-84. PubMed ID: 12020983
[TBL] [Abstract][Full Text] [Related]
4. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
Goldstein SR; Bhattoa HP; Neven P; Cox DA; Dowsett SA; Alam J; Sipos A; Muram D
Menopause; 2012 Jan; 19(1):41-7. PubMed ID: 21993078
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and treatment of postmenopausal uterine bleeding by hysteroscopy].
Liu Y; Zhou Y; Wen H
Zhonghua Fu Chan Ke Za Zhi; 1995 Dec; 30(12):732-4. PubMed ID: 8728918
[TBL] [Abstract][Full Text] [Related]
6. [Effects of raloxifene on other organs without bone: uterus].
Nozaki M
Clin Calcium; 2004 Oct; 14(10):55-60. PubMed ID: 15577132
[TBL] [Abstract][Full Text] [Related]
7. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60.
Cohen FJ; Watts S; Shah A; Akers R; Plouffe L
Obstet Gynecol; 2000 Jan; 95(1):104-10. PubMed ID: 10636511
[TBL] [Abstract][Full Text] [Related]
8. Endometrial pathology in postmenopausal women with no bleeding.
Genc M; Genc B; Sahin N; Celik E; Turan GA; Gur EB; Guclu S
Climacteric; 2015 Apr; 18(2):241-5. PubMed ID: 25017611
[TBL] [Abstract][Full Text] [Related]
9. The significance of an 'insufficient' Pipelle sample in the investigation of post-menopausal bleeding.
Farrell T; Jones N; Owen P; Baird A
Acta Obstet Gynecol Scand; 1999 Oct; 78(9):810-2. PubMed ID: 10535347
[TBL] [Abstract][Full Text] [Related]
10. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study.
Gebauer G; Hafner A; Siebzehnrübl E; Lang N
Am J Obstet Gynecol; 2001 Jan; 184(2):59-63. PubMed ID: 11174480
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study.
de Azevedo GD; do Prado MF; Ferriani RA; dos Reis RM; Berezowski AT; Ribeiro TF; Silva E; de Oliveira Maranhão TM; Silva de Sá MF
Maturitas; 2004 Mar; 47(3):195-200. PubMed ID: 15036489
[TBL] [Abstract][Full Text] [Related]
12. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
13. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129
[TBL] [Abstract][Full Text] [Related]
14. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T;
BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
[TBL] [Abstract][Full Text] [Related]
15. Mood effect of raloxifene in postmenopausal women.
Jarkova NB; Martenyi F; Masanauskaite D; Walls EL; Smetnik VP; Pavo I
Maturitas; 2002 May; 42(1):71-5. PubMed ID: 12020982
[TBL] [Abstract][Full Text] [Related]
16. [The value of ultrasonography in diagnosis of atypical endometrial hyperplasia in postmenopausal women].
Starczewski A; Brodowska A; Strojny K; Puchalski A; Mieczkowska E; Szydłowska I
Przegl Lek; 2005; 62(4):227-9. PubMed ID: 16229240
[TBL] [Abstract][Full Text] [Related]
17. A postmenopausal woman developed a giant endometrial polyp during Raloxifene treatment.
Kutuk MS; Goksedef BP
J Obstet Gynaecol; 2011 Oct; 31(7):672. PubMed ID: 21973134
[No Abstract] [Full Text] [Related]
18. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
[TBL] [Abstract][Full Text] [Related]
19. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
[TBL] [Abstract][Full Text] [Related]
20. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
